- Home
- DSGN vs TSI Comparison
DSGN vs TSI Comparison
Compare DSGN & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- TSI
- Stock Information
- Founded
- DSGN 2017
- TSI 1987
- Country
- DSGN United States
- TSI United States
- Employees
- DSGN N/A
- TSI N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- TSI Investment Managers
- Sector
- DSGN Health Care
- TSI Finance
- Exchange
- DSGN Nasdaq
- TSI Nasdaq
- Market Cap
- DSGN 224.8M
- TSI 234.6M
- IPO Year
- DSGN 2021
- TSI N/A
- Fundamental
- Price
- DSGN $3.71
- TSI $4.90
- Analyst Decision
- DSGN Hold
- TSI
- Analyst Count
- DSGN 1
- TSI 0
- Target Price
- DSGN $4.00
- TSI N/A
- AVG Volume (30 Days)
- DSGN 93.8K
- TSI 106.8K
- Earning Date
- DSGN 08-04-2025
- TSI 01-01-0001
- Dividend Yield
- DSGN N/A
- TSI 7.46%
- EPS Growth
- DSGN N/A
- TSI N/A
- EPS
- DSGN N/A
- TSI N/A
- Revenue
- DSGN N/A
- TSI N/A
- Revenue This Year
- DSGN N/A
- TSI N/A
- Revenue Next Year
- DSGN N/A
- TSI N/A
- P/E Ratio
- DSGN N/A
- TSI N/A
- Revenue Growth
- DSGN N/A
- TSI N/A
- 52 Week Low
- DSGN $2.60
- TSI $4.48
- 52 Week High
- DSGN $7.77
- TSI $4.87
- Technical
- Relative Strength Index (RSI)
- DSGN 47.78
- TSI 29.71
- Support Level
- DSGN $3.66
- TSI $4.90
- Resistance Level
- DSGN $3.84
- TSI $4.94
- Average True Range (ATR)
- DSGN 0.25
- TSI 0.04
- MACD
- DSGN -0.02
- TSI -0.01
- Stochastic Oscillator
- DSGN 18.06
- TSI 0.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.